Opinion|Videos|July 17, 2024
ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC
Author(s)Jason Porter, MD
Key Takeaways
- Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial.
- The trial results suggest osimertinib may become a new standard of care for patients with EGFR-mutated NSCLC, enhancing treatment strategies.
Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the data that was presented at the 2024 ASCO Annual Meeting on the progression-free survival from the phase 3 trial LAURA of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC without progression after definitive CRT.
- What are your key takeaways from this study and how will it impact the current standard of care for EGFR-mutated NSCLC?
Advertisement
Related to this article
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5